Neurogenic lower urinary tract dysfunction (neurogenic bladder), screening for bladder cancer Cancer
Conditions
Interventions
This study will recruit two groups of participants.
1. NLUTD Group: patients suffering from neurogenic lower urinary tract dysfunction (NLUTD) for at least 5 years, who have been scheduled for cystos
Sponsors
Aristotle University of Thessaloniki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Neurogenic lower urinary tract dysfunction group: 1. Neurogenic lower urinary tract dysfunction duration for at least 5 years scheduled for cystoscopy, wash cytology and bladder biopsy 2. Age 18 years or older 3. Consent to provide urine sample and bladder tissue Control group (healthy volunteers): 1. Age 18 years or older 2. Consent to provide urine sample
Exclusion criteria
Exclusion criteria: Neurogenic lower urinary tract dysfunction group: 1. Prior diagnosis and treatment of bladder cancer 2. History of other urinary tract malignancy Control group (healthy volunteers): 1. Lower urinary tract symptoms 2. History of urinary tract malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA methylation of a panel of five genes’ promoters (Ras-Association domain Family member 1 [RASSF1], Retinoid Acid Receptor beta [RARß], Death-Associated Protein Kinase [DAPK], Telomerase Reverse Transcriptase [TERT] and Adenomatous Polyposis Coli [APC]) in urine measured using Quantitative Methylation Specific PCR at a single timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| DNA hypermethylation of the panel of five genes’ promoters (RASSF1, RARß, DAPK, TERT and APC) in the bladder tissue of patients suffering from neurogenic lower urinary tract dysfunction (NLUTD) measured using Quantitative Methylation Specific PCR at a single timepoint | — |
Countries
Greece
Outcome results
None listed